MedTrace Logo

Bioinformation Therapy for Pancreatic Cancer

NCT03239184 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-01-25

No results posted yet for this study

Summary

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable pancreatic cancer.

Conditions

  • Unresectable Pancreatic Cancer

Interventions

DEVICE

Cancer ablation

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound

DRUG

Life information rehabilitation therapy

Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Sponsors & Collaborators

  • Shengxin Biotechnology Institute, Beijing

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-09-01
Completion
2018-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03239184 on ClinicalTrials.gov